Metformine Zentiva (Metformin Hydrochloride)

Metformine Zentiva, a biguanide, is employed in the management of disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Gestational diabetes: helps achieve target glucose control during pregnancy.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK), which enhances glucose uptake in muscle and adipose tissue while decreasing intestinal glucose absorption.

Metformine Zentiva may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools, especially early in therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: life‑threatening metabolic acidosis, especially in renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hypoglycemia: when combined with other glucose‑lowering agents.
• Anemia: rare hemolytic events.
• Pancreatitis: inflammation of the pancreas.

Before initiating Metformine Zentiva, certain safety considerations are recommended.

• Renal function assessment: avoid use in severe renal impairment.
• Hepatic function monitoring: contraindicated in active liver disease.
• Risk of lactic acidosis: evaluate for conditions predisposing to hypoxia.
• Elderly patients: start at lower dose and monitor tolerance.
• Alcohol consumption: limit intake to reduce acidosis risk.
• Store at room temperature: keep in the original packaging, protect from moisture.

Metformine Zentiva can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis.
• Cimetidine: can increase metformin plasma concentrations.
• Carbonic anhydrase inhibitors (e.g., acetazolamide): raise risk of acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics (loop or thiazide): can affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and electrolytes.